Global TB Network: working together to eliminate tuberculosis

Silva, Denise Rossato; Rendón, Adrián; Alffenaar, Jan-Willem; Chakaya, Jeremiah Muhwa; Sotgiu, Giovanni; Esposito, Susanna; Migliori, Giovanni Battista

doi:10.1590/s1806-37562018000000279

Cited by 21 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time, through the use of modern technology including sequencing, therapeutic drug monitoring, clinical decision support systems and digital solutions, even patients experiencing multiple failures and/or toxicities with unusual and/or more complex resistance profiles could be cured. In this regard, national and international bodies of experts (TB consilia) may be important in supporting personalised design of regimens for challenging resistance patterns [40].…”

Section: Discussionmentioning

confidence: 99%

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

2019

Self Cite

View full text Add to dashboard Cite

Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20–24 months), toxicity, costs and sub-optimal outcomes.After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9–10 months.The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.

show abstract

Section: Discussionmentioning

confidence: 99%

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Obviously, the best solution would be the implementation of integrated TB policy dedicated to immigrants in all the EU member states, e.g. the algorithms for TB control proposed by experts [36][37][38][39][40][41]. Some elements of these procedures are The above data suggest that the migration from Africa and the Middle East to the EU has been accompanied by a massive migration from Ukraine to the Central and Eastern European Countries.…”

Section: Action Plansmentioning

confidence: 99%

“…Oczywiście najlepszym rozwiązaniem byłoby wdrożenie zintegrowanej polityki zwalczania gruźlicy wśród imigrantów we wszystkich państwach członkowskich UE, np. algorytmy kontroli TB zaproponowane wcześniej przez ekspertów [36][37][38][39][40][41]. Niektóre elementy z tych procedur są obecnie realizowane w części krajów europejskich.…”

Section: Plany Działańunclassified

Immigrants and tuberculosis in Europe – are we prepared for outbreak?

Koper

Pajączek

Kryczka

2020

Pielegniarstwo XXI Wieku / Nursing in the 21st Century

View full text Add to dashboard Cite

Introduction. International travel and immigration have led to a rise in the incidence of tuberculosis in European countries, mainly due to migration from Africa and the Middle East.Aim. In this article we point to an additional migration path - from Ukraine - and the threat of tuberculosis associated with this migration and we discuss our preparation for an increase in the incidence of this disease.Discussion. It is estimated that about 1.5-2.5 million Ukrainians work or live in Poland or the EU. This results from the implementation of some EU directives and Polish law regulations, which simplified an access of the Ukrainian citizens to the European labor market. Importantly, Ukraine is one of the 18 high-priority countries to fight tuberculosis in the WHO European Region and among the top 20 highest drug-resistant tuberculosis burden countries in the world. More importantly, there is no unitary tuberculosis screening program for migrants in the EU member states. For this reason, we have no reliable data on tuberculosis burden in any nationality group of immigrants in Europe, including Ukrainians.Conclusions. Nurses have always dealt with infectious diseases, they have always been and will be the last line of defense against the epidemic. Any epidemic, including tuberculosis. Perhaps, in the absence of an integrated tuberculosis policy in Europe, our only future are the experience, skills and dedication of nurses.

show abstract

“…By the end of January 2019, 16 countries had reported a total of 891 AEs to this database (C. Halleux, personal communication). Third, 27 countries that reportedly faced difficulties in submitting data to the global aDSM database have committed to report to the recently implemented Global TB Network hosted by the World Association for Infectious Diseases and Immunological Disorders (www.waidid.org/) [63,64]. So far, 18 countries have shared data, which were planned for publication in the second quarter of 2019 [64].…”

Section: Why Active Drug Safety Monitoring?mentioning

confidence: 99%

Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences

et al. 2019

View full text Add to dashboard Cite

New drugs and shorter treatments for drug-resistant tuberculosis (DR-TB) have become available in recent years and active pharmacovigilance (PV) is recommended by the World Health Organization (WHO) at least during the early phases of implementation, with active drug safety monitoring and management (aDSM) proposed for this. We conducted a literature review of papers reporting on aDSM. Up to 18 April, 2019, results have only been published from one national aDSM programme. Because aDSM is being introduced in many low- and middle-income countries, we also report experiences in introducing it into DR-TB treatment programmes, targeting the reporting of a restricted set of adverse events (AEs) as per WHO-recommended aDSM principles for the period 2014–2017. Early beneficial effects of active PV for TB patients include increased awareness about the occurrence, detection and management of AEs during TB treatment, and the increase of spontaneous reporting in some countries. However, because PV capacity is low in most countries and collaboration between national TB programmes and national PV centres remains weak, parallel and coordinated co-development of the capacities of both TB programmes and PV centres is needed.

show abstract

Global TB Network: working together to eliminate tuberculosis

Cited by 21 publications

References 14 publications

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

Immigrants and tuberculosis in Europe – are we prepared for outbreak?

Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences

Contact Info

Product

Resources

About